Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03557294
Other study ID # 1R01DA044125
Secondary ID R01DA044125
Status Completed
Phase Phase 4
First received
Last updated
Start date May 7, 2018
Est. completion date April 16, 2022

Study information

Verified date April 2022
Source Arizona State University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The primary goal of the proposed research is to test whether varenicline (Chantix) is safe and effective as an over-the-counter (OTC) medication.


Description:

Given the recent research on varenicline showing that it is more effective than nicotine patch and bupropion, and with the removal of the box warning, research is needed to assess whether smokers can use varenicline without a prescription and formal behavioral support. To test this, the primary goal of the proposed research is to test whether varenicline is a candidate for switching from prescription (Rx) to OTC, and whether a dose lower than that currently approved is as effective in an OTC environment. To understand the within-person mechanisms explaining how and when OTC varenicline might improve cessation outcomes, the investigators also propose to assess experience with OTC varenicline via (a) ecological momentary assessment (EMA). Primary Objectives: 1. To assess the safety and effectiveness of the current FDA-approved 1 mg b.i.d. varenicline for smoking cessation in comparison with placebo when used in a simulated OTC study condition. 2. To assess the safety and effectiveness of .5mg b.i.d. varenicline in comparison with 1mg b.i.d. varenicline and placebo when used in a simulated OTC study condition.


Recruitment information / eligibility

Status Completed
Enrollment 307
Est. completion date April 16, 2022
Est. primary completion date April 16, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 21 Years and older
Eligibility Inclusion Criteria for the In-person Cohort 1. 21 years of age or older 2. Self-reported daily smoker 3. Breath CO > 10ppm 4. Motivated to quit smoking completely within five weeks of the Screening Visit (>5 on reported motivation) 5. Capable of and agree to complete study requirements 6. Literate in English, self-report 7. Must be available for the duration of study 8. Informed consent obtained 9. Willing and able to provide additional data between visits using ecological momentary assessment (EMA) 10. Must own study compatible smart-phone (iPhone or Android) Exclusion Criteria for the In-person Cohort 1. Any self-report, diagnosis or treatment of heart attack, unstable angina, angioedema, seizures, cerebrovascular accident (CVA) within the last six months. 2. Any self-report, diagnosis or treatment of bipolar, schizophrenia or suicidal ideation within the last six months. (For suicidal ideation a score of =7 on the Suicidal Behavior Questionnaire, see Appendix 15) 3. Self-report of diagnosis or treatment for depression within the past six months, unless participant has written permission by their healthcare provider to participate 4. Systolic blood pressure 160 or higher and/or diastolic blood pressure 100 or higher (see site applicable SOP for Evaluating and Reporting Blood Pressure and Appendices 5 and 6 for participant handouts) 5. History of renal disease 6. Allergy to any of the ingredients in varenicline 7. Participation in another smoking cessation program or any type of clinical trial in the past 3 months 8. Use of any smoking cessation medication in the past three months 9. Any other medical condition(s) which the licensed study physician deems unacceptable for participation in this study 10. Positive drug screen indicating possible substance abuse (eg opiates, amphetamines, benzodiazepines, cocaine or other substances), unless participant can show that the medication has been prescribed by licensed clinical provider. 11. Consume greater than 21 alcohol drinks per week. 12. No two members of the same household may participate in this study 13. No study staff or their immediate family may participate in the study 14. Females who are pregnant, breast feeding, or not currently using a medically approved form of birth control and unwilling to do so. Acceptable methods of birth control include abstinence, oral contraceptives, the contraceptive patch, the contraceptive ring, and condoms. Inclusion Criteria for the Remote Cohort 1. 21 years of age or older 2. Self-reported daily smoker 3. Positive cotinine from urine sample 4. Motivated to quit smoking completely within five weeks of the Screening Visit (>5 on reported motivation) 5. Capable of and agree to complete study requirements 6. Literate in English, self-report 7. Must be available for the duration of study 8. Informed consent obtained 10. Must own study compatible smart-phone (iPhone or Android) 11. Must be a current resident of the United States Exclusion Criteria for the Remote Cohort 1. Any self-report, diagnosis or treatment of heart attack, unstable angina, angioedema, seizures, cerebrovascular accident (CVA) within the last six months. 2. Any self-report, diagnosis or treatment of bipolar, schizophrenia or suicidal ideation within the last six months. (For suicidal ideation a score of =7 on the Suicidal Behavior Questionnaire, see Appendix 15) 3. Self-report of diagnosis or treatment for depression within the past six months, unless participant has written permission by their healthcare provider to participate 4. History of renal disease 5. Allergy to any of the ingredients in varenicline 6. Participation in another smoking cessation program or any type of clinical trial in the past 3 months 7. Use of any smoking cessation medication in the past three months 8. Any other medical condition(s) which the licensed study physician deems unacceptable for participation in this study 9. Consume greater than 21 alcohol drinks per week. 10. No two members of the same household may participate in this study 11. No study staff or their immediate family may participate in the study 12. Females who are pregnant, breast feeding, or not currently using a medically approved form of birth control and unwilling to do so. Acceptable methods of birth control include abstinence, oral contraceptives, the contraceptive patch, the contraceptive ring, and condoms.

Study Design


Intervention

Drug:
1.0mg Varenicline b.i.d.
Varenicline is classified as a selective nicotine receptor partial agonist (SNRPA) that works both to stimulate the nicotine receptor and block smoking reward at the a4ß2 nicotinic receptor subtype.
0.5mg Varenicline b.i.d.
Varenicline is classified as a selective nicotine receptor partial agonist (SNRPA) that works both to stimulate the nicotine receptor and block smoking reward at the a4ß2 nicotinic receptor subtype.
0.0mg placebo Varenicline b.i.d.
Product that looks like active varenicline, but contains no active ingredient

Locations

Country Name City State
United States Los Angeles Clinical Trials Burbank California
United States Arizona State University Phoenix Arizona

Sponsors (5)

Lead Sponsor Collaborator
Arizona State University Los Angeles Clinical Trials, National Institute on Drug Abuse (NIDA), Pfizer, University of Nevada, Reno

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Breath carbon monoxide verified abstinence from smoking cigarettes Participants will provide self reported smoking status that has been verified by breath carbon monoxide Week 12
Secondary Adverse events Participants will be asked to report adverse events Week 2 visit
Secondary Adverse events Participants will be asked to report adverse events Week 4 visit
Secondary Adverse events Participants will be asked to report adverse events Week 8 visit
Secondary Adverse events Participants will be asked to report adverse events Week 12 visit
Secondary Adverse events Participants will be asked to report adverse events Week 13 visit
Secondary Adverse events A subset of participants will be asked to report adverse events via ecological momentary assessment (EMA). EMA asks questions via the participant mobile phone on multiple occasions, primarily at random Change in adverse events from baseline to week 2 as measured by 5 daily EMA prompts
Secondary Withdrawal symptoms and craving Participants will be asked to report withdrawal symptoms, as measured by the Minnesota Nicotine Withdrawal Scale (MNWS). Scores can be between 0 (absent) - 4 (severe), and the average scores will be assessed. week 2 visit
Secondary Withdrawal symptoms and craving Participants will be asked to report withdrawal symptoms, as measured by the Minnesota Nicotine Withdrawal Scale (MNWS). Scores can be between 0 (absent) - 4 (severe), and the average scores will be assessed. week 4 visit
Secondary Withdrawal symptoms and craving Participants will be asked to report withdrawal symptoms, as measured by the Minnesota Nicotine Withdrawal Scale (MNWS). Scores can be between 0 (absent) - 4 (severe), and the average scores will be assessed. week 8 visit
Secondary Withdrawal symptoms and craving Participants will be asked to report withdrawal symptoms, as measured by the Minnesota Nicotine Withdrawal Scale (MNWS). Scores can be between 0 (absent) - 4 (severe), and the average scores will be assessed. week 12 visit
Secondary Withdrawal symptoms and craving Participants will be asked to report withdrawal symptoms, as measured by the Minnesota Nicotine Withdrawal Scale (MNWS). Scores can be between 0 (absent) - 4 (severe), and the average scores will be assessed. week 13 visit
Secondary Craving Participants will be asked to report craving via ecological momentary assessment (EMA). EMA asks questions via the participant mobile phone on multiple occasions, primarily at random change in craving from baseline to week 2 as measured by 5 daily EMA prompts
Secondary Breath carbon monoxide verified abstinence from smoking cigarettes Participants who self report not smoking will be asked to have smoking status verified by breath carbon monoxide Week 26
See also
  Status Clinical Trial Phase
Completed NCT04043728 - Addressing Psychological Risk Factors Underlying Smoking Persistence in COPD Patients: The Fresh Start Study N/A
Completed NCT03999411 - Smartphone Intervention for Smoking Cessation and Improving Adherence to Treatment Among HIV Patients Phase 4
Completed NCT04617444 - The ESTxENDS Trial- Substudy on Effects of Using Electronic Nicotine Delivery Systems (ENDS) on Olfactory Function N/A
Completed NCT02796391 - Facilitating Smoking Cessation With Reduced Nicotine Cigarettes Phase 2
Completed NCT03397511 - Incorporating Financial Incentives to Increase Smoking Cessation Among Asian Americans Residing in New York City N/A
Not yet recruiting NCT05188287 - A Culturally Tailored Smartphone Application for African American Smokers N/A
Recruiting NCT05264428 - The Effect of Honey on Lessening the Withdrawal Symptoms N/A
Recruiting NCT05846841 - Personalized Tobacco Treatment in Primary Care (MOTIVATE) N/A
Completed NCT04133064 - Assessment of the Pivot Breath Sensor: Single-Arm Cohort Study N/A
Completed NCT03187730 - Integrating Financial Management Counseling and Smoking Cessation Counseling to Reduce Health and Economic Disparities in Low-Income Immigrants Phase 4
Completed NCT03474783 - To Explore the Factors Affecting the Effectiveness of Smoking Cessation N/A
Completed NCT04635358 - Feasibility Study of Smoking Cessation for the Staff of a Hospital Center N/A
Terminated NCT03670264 - BE Smokefree: Behavioral Economics Incentives to Engage Adolescents in Smoking Cessation N/A
Not yet recruiting NCT06307496 - VIDeOS for Smoking Cessation N/A
Completed NCT02905656 - Strategies to Promote Cessation in Smokers Who Are Not Ready To Quit N/A
Completed NCT02997657 - Positive Psychotherapy for Smoking Cessation Enhanced With Text Messaging: A Randomized Controlled Trial N/A
Completed NCT03206619 - A Health Recommeder System to Tailor Message Preferences in a Smoking Cessation Programme
Completed NCT02239770 - Pharmacokinetics of Nicotine Film in Smokers N/A
Completed NCT02562521 - A Smoking Cessation Intervention for Yale Dining Employees Phase 4
Recruiting NCT02422914 - Benefits of Tobacco Free Cigarette N/A